100
Participants
Start Date
March 31, 2016
Primary Completion Date
December 31, 2022
Study Completion Date
December 31, 2026
DS-3201b
DS-3201 to be administered orally once daily in each 28-day cycle.
DS-3201b
DS-3201 to be administered orally once daily in each 28-day cycle at the recommended dose for expansion.
Weill Cornell Medicine, New York
Memorial Sloan Kettering Cancer Center, New York
Thomas Jefferson University, Philadelphia
Duke University Medical Center, Durham
Emory University, Atlanta
The Ohio State University Wexner Medical Center and James Cancer Hospital, Columbus
City of Hope National Medical center, Duarte
Yale University, New Haven
Dana-Farber Cancer Institute, Boston
Hackensack University Medical Center, Hackensack
Nagoya City University Hospital, Nagoya
National Cancer Center Hospital East, Kahiwa-shi
Iwate Medical University Hospital, Morioka
Imamura General Hospital, Kagoshima
Kagoshima University Hospital, Kagoshima
Kumamoto University Hosipital, Kumamoto
Nagasaki University Hospital, Nagasaki
University of the Ryukyus Hospital, Nakagami-gun
The Institute of Medical Science, The University of Tokyo, Minato-ku
National Cancer Center Hospital, Chūōku
Lead Sponsor
Collaborators (1)
Daiichi Sankyo
INDUSTRY
Daiichi Sankyo Co., Ltd.
INDUSTRY